2025 IMMUNIZATION CALENDAR (part 1)

ROUTINE VACCINES:

vaccines that may or may not be included in the NIP but are to be routinely used for children according to:

• Philippine Pediatric Society (PPS)

• Pediatric Infectious Disease Society of the Philippines (PIDSP)

• Philippine Foundation for Vaccination (PFV).

RECOMMENDED VACCINES FOR SPECIAL GROUP/SITUATIONS:

These are vaccines that should be given to certain groups or situations

PHILIPPINE NATIONAL IMMUNIZATION PROGRAM (NIP) VACCINES:

• BCG, monovalent Hepatitis B, Pentavalent vaccine (DTwP-Hib-HepB), Bivalent OPV, IPV, PCV, MMR/MR

• School-based Immuniza0on Program: MR, Td, HPV

Bacille Calmette-Guerin (BCG)

type

Live attenuated vaccine

Bacille Calmette-Guerin (BCG)

minimum age

At birth

Bacille Calmette-Guerin (BCG)

route of administration

Intradermal

Bacille Calmette-Guerin (BCG)

routine vaccination

Single dose

Bacille Calmette-Guerin (BCG)

is given __

at the earliest possible age after birth, preferably within the first 2 months of life.

Bacille Calmette-Guerin (BCG)

dose: <12 months

0.05 mL

Bacille Calmette-Guerin (BCG)

dose: >/= 12 months

0.10 mL

Bacille Calmette-Guerin (BCG)

For healthy infants and children >2 months who are not given BCG at birth, purified protein derivative (PPD) prior to vaccination __

is not necessary unless the child is included in “special situations”.

Bacille Calmette-Guerin (BCG)

CATCH-UP RECOMMENDATION

For healthy infants and children >2 months who are not given BCG at birth, purified protein derivative (PPD) prior to vaccination is not necessary unless the child is included in “special situations”.

Bacille Calmette-Guerin (BCG)

For Infants and children > 2 months, PPD is recommended prior to BCG vaccination if any of the following is present:

• Congenital Tuberculosis

• History of close contact to a known or suspected TB case

• Clinical and/or chest x-ray findings suggestive of TB

induration of 5 mm is considered positive, and BCG is no longer recommended

Bacille Calmette-Guerin (BCG)

People living with HIV (PLHIV) who are receiving ART, are clinically well, and are immunologically stable

• CD4% >25% for children aged <5 years

• CD4 count ≥ 200 if aged >5 years

should be vaccinated with BCG.

Bacille Calmette-Guerin (BCG)

Neonates of unknown HIV status born to women living with HIV

should be vaccinated if no clinical evidence suggests HIV infection, regardless of whether the mother is receiving ART or not

Bacille Calmette-Guerin (BCG)

special considerations

• For Infants and children > 2 months, PPD is recommended prior to BCG vaccination if any of the following is present:

  1. Congenital Tuberculosis

  2. History of close contact to a known or suspected TB case

  3. Clinical and/or chest x-ray findings suggestive of TB

induration of 5 mm is considered positive, and BCG is no longer recommended

• People living with HIV (PLHIV) who are receiving ART, are clinically well, and are immunologically stable CD4% >25% for children aged <5 years, CD4 count ≥ 200 if aged >5 years should be vaccinated with BCG.

• Neonates of unknown HIV status born to women living with HIV should be vaccinated if no clinical evidence suggests HIV infection, regardless of whether the mother is receiving ART or not

Hepatitis B Vaccine (HBV)

type

Inactivated vaccine

Hepatitis B Vaccine (HBV)

minimum age

At birth

Hepatitis B Vaccine (HBV)

route of administration

Intramuscular (IM)

Hepatitis B Vaccine (HBV)

routine vaccination

3 dose series

Hepatitis B Vaccine (HBV)

1st dose

Birth dose (monovalent HBV to all newborns ≥ 2kgs within 24 hours of life)

Hepatitis B Vaccine (HBV)

2nd dose

1 to 2 months after birth dose

Hepatitis B Vaccine (HBV)

3rd dose

Administered not earlier than 24 weeks

Hepatitis B Vaccine (HBV)

4th dose

Needed if the last dose was given at <24 weeks old

Hepatitis B Vaccine (HBV)

When provided as part of NIP, HBV is administered as

• birth dose at 0 months and a 3 dose series at 6, 10, and 14 weeks of age.

• A full series of 4 doses including the birth dose, is adequate.

Hepatitis B Vaccine (HBV)

For non-responders to the initial vaccination series:

A second series of 0, 1, and 6 month vaccination is recommended.

Hepatitis B Vaccine (HBV)

Routine serology testing

is not recommended for immunocompetent individuals.

Hepatitis B Vaccine (HBV)

CATCH-UP RECOMMENDATION: For unimmunized children

3-dose series at 0, 1, and 6 months

Hepatitis B Vaccine (HBV)

CATCH-UP RECOMMENDATION: Minimum intervals are as follows

• Dose 1 to 2 = 4 weeks

• Dose 2 to 3 = 8 weeks

• Dose 1 to 3 = 16 weeks

Hepatitis B Vaccine (HBV)

special consideration

• For infants born to HBsAg (+) mothers(preterm or term infants)

• For infants born to mothers with unknown HBsAg status

• Post-vaccinatioon serology testing and revaccination

Hepatitis B Vaccine (HBV)

• For infants born to HBsAg (+) mothers(preterm or term infants)

• Administer HBV* and HBIG (0.5mL) within 12 hours of life.

• HBIG should be administered not later than 7 days of age, if not immediately available

Hepatitis B Vaccine (HBV)

• For infants born to mothers with unknown HBsAg status:

  • With birth weight ≥2 kgs,

• administer HBV within 12 hours of birth and determine the mother’s HBsAg as soon as possible.

• If HBsAg (+), administer HBIG not later than 7 days of age.

Hepatitis B Vaccine (HBV)

• For infants born to mothers with unknown HBsAg status:

  • With birth weight <2 kgs,

• administer HBIG in addition to HBV within 12 hours of life.

Hepatitis B Vaccine (HBV)

• For infants born to mothers with unknown HBsAg status:

  • For infants born <2 kgs,

• the 1st dose received at birth is not counted as part of the vaccine series. Additional 3 HBV doses are needed.

Hepatitis B Vaccine (HBV)

• Post-vaccination serology testing and revaccination (if anti-HBs <10mIU/mL) is recommended for certain populations, including:

• Infants born to HBsAg-positive mothers

• Persons who are pre-dialysis or on maintenance dialysis

• Other immunocompromised persons (e.g. HIV, transplant patients, on chemotherapy)

Diphtheria, Tetanus, Pertussis (DTP)

type

Inactivated vaccine (provided as DTP-containing combination vaccine)

Diphtheria, Tetanus, Pertussis (DTP)

min age

6 wks

Diphtheria, Tetanus, Pertussis (DTP)

max age

7 yrs

Diphtheria, Tetanus, Pertussis (DTP)

route of admin

Intramuscular (IM)

Diphtheria, Tetanus, Pertussis (DTP)

routine vaccination: primary series (# of doses)

3-dose series

Diphtheria, Tetanus, Pertussis (DTP)

routine vaccination: primary series (minimum interval)

4 weeks

Diphtheria, Tetanus, Pertussis (DTP)

routine vaccination: booster doses (n# of doses)

• 12-18 mos. (DTP)

• 4-6 yrs. (DTP)

• 7-18 yrs. (Tdap)

Diphtheria, Tetanus, Pertussis (DTP)

routine vaccination: min interval

4 yrs

The NIP provides DTP-containing combination vaccines at

6, 10 and 14 weeks

Diphtheria, Tetanus, Pertussis (DTP)

CATCH-UP RECOMMENDATION: For unvaccinated children 4 months to 6 years old

• • Dose 1 to 2 = 4 weeks apart

• Dose 2 to 3 = 4 weeks apart

• Dose 3 to 4 = 6 months apart

• Dose 4 to 5* = at least 4 years apart

Diphtheria, Tetanus, Pertussis (DTP)

• *A 5th dose is not necessary if

the 4th dose was administered at age 4 years or older

Diphtheria, Tetanus, Pertussis (DTP)

CATCH-UP RECOMMENDATION: For delayed or interrupted DTP-containing series

Resume the series without repeating previous doses.

Diphtheria, Tetanus, Pertussis (DTP)

SPECIAL CONSIDERATIONS:

• History of tetanus toxoid containing vaccine: Unknown or <3 doses: Clean, minor wounds

DTaP

Diphtheria, Tetanus, Pertussis (DTP)

SPECIAL CONSIDERATIONS:

• History of tetanus toxoid containing vaccine: Unknown or <3 doses: all other wounds

DTaP

Diphtheria, Tetanus, Pertussis (DTP)

SPECIAL CONSIDERATIONS:

• History of tetanus toxoid containing vaccine: 3 or more doses: Clean, minor wounds

None, if <10 years since last tetanus-containing vaccine dose

Diphtheria, Tetanus, Pertussis (DTP)

SPECIAL CONSIDERATIONS:

• History of tetanus toxoid containing vaccine: 3 or more doses: all other wounds

DTaP, if >/= 5 years since last tetanus-containing vaccine dose

Poliovirus Vaccine

type

Inactivated Polio Vaccine (IPV)

Live-attenuated Oral Polio Vaccine (OPV)

Poliovirus Vaccine

min age

6 wks

Poliovirus Vaccine

route of admin: IPV

Intramuscular (IM)

Poliovirus Vaccine

route of admin: opv

per oral (PO)

Poliovirus Vaccine

routine vaccination: primary series

• 3-dose series

• Minimum age: 6 weeks old

• Minimum interval: 4 weeks

Poliovirus Vaccine

routine vaccination: 1st booster

12-18 months old (interval of 6 months from 3rd dose)

Poliovirus Vaccine

routine vaccination: 2nd booster

4-6 years old

Poliovirus Vaccine

routine vaccination: nip sched (opv)

3 doses at 6, 10, 14 weeks old

Poliovirus Vaccine

routine vaccination: nip sched (ipv)

• 1st dose: 14 weeks old

• 2nd dose: 9 months old

Poliovirus Vaccine

CATCH-UP RECOMMENDATION

• Given as Inactivated Polio Vaccine

• For unvaccinated children ages >/= 4 months to 18 years

• For partially vaccinated children ages >/= 4 months to 18 years

Poliovirus Vaccine

CATCH-UP RECOMMENDATION:

• For unvaccinated children ages >/= 4 months to 18 years, complete the series as follows

• Dose 1 to 2: Minimum interval is 4 weeks

• Dose 2 to 3: Minimum interval is 6 months

• Dose 3 to 4: Minimum interval is 6 months

Poliovirus Vaccine

• Dose 4 is not necessary if

3rd dose was given at >/= age 4 years and at least 6 months after the previous dose.

Poliovirus Vaccine

CATCH-UP RECOMMENDATION: For partially vaccinated children ages >/= 4 months to 18 years

continue the series as above. No need to restart.

Poliovirus Vaccine

SPECIAL CONSIDERATIONS

• People Living with HIV (PLHIV) / Immunocompromised

• OPV may be given in addition to routine polio vaccination as part of DOH-Supplemental Immunization Activity (SIA) Program.

Poliovirus Vaccine

SPECIAL CONSIDERATIONS

• People Living with HIV (PLHIV) / Immunocompromised

• OPV is contraindicated.

• IPV is the only polio vaccine recommended for people with immunodeficiency and people in their households.

Poliovirus Vaccine

SPECIAL CONSIDERATIONS

• OPV may be given in addition to routine polio vaccination as part of DOH-Supplemental Immunization Activity (SIA) Program.

In such cases, OPV may be given earlier than 6 weeks, though it is not counted as part of the 3-dose primary series.

Haemophilus influenzae type b Conjugate Vaccine (Hib vaccine)

type

Inactivated vaccine

Haemophilus influenzae type b Conjugate Vaccine (Hib vaccine)

min age

6 weeks

Haemophilus influenzae type b Conjugate Vaccine (Hib vaccine)

route of admin

Intramuscular (IM)

Haemophilus influenzae type b Conjugate Vaccine (Hib vaccine)

routine vaccination: primary series

• 3 doses

• 4 weeks interval

Haemophilus influenzae type b Conjugate Vaccine (Hib vaccine)

routine vaccination: booster dose

• 1 dose

• age: 12-15 months, with interval of 6 mos. from the 3rd dose

Haemophilus influenzae type b Conjugate Vaccine (Hib vaccine)

CATCH-UP RECOMMENDATION: For children ages 4 months to 6 years who received their first dose at 7-11months

• Give 3 doses

• Dose 1 to 2 = 4 weeks interval

• Dose 2 to 3 = at 12-15 months or 8 weeks after the 2nd dose (whichever is later)

Haemophilus influenzae type b Conjugate Vaccine (Hib vaccine)

CATCH-UP RECOMMENDATION: For children ages 4 months to 6 years who received their first dose at

• Give 2 doses only

• Dose 1 to 2 = 8 weeks interval

Haemophilus influenzae type b Conjugate Vaccine (Hib vaccine)

CATCH-UP RECOMMENDATION: For children ages 4 months to 6 years who received their first dose at >/= 15 months

No further doses needed

Haemophilus influenzae type b Conjugate Vaccine (Hib vaccine)

CATCH-UP RECOMMENDATION: .For unvaccinated children aged 5 years or older who are not considered high-risk

• Catch-up vaccination not required

Haemophilus influenzae type b Conjugate Vaccine (Hib vaccine)

High-risk individuals:

• Chemotherapy or radiation treatment

• Hematopoietic stem cell transplant (HSCT)

• Anatomic/functional asplenia including sickle cell disease

• Elective splenectomy

• HIV infection

• Immunoglobulin or early component complement deficiency

Haemophilus influenzae type b Conjugate Vaccine (Hib vaccine)

.For high-risk children ages 12 to 59 months:

• Unimmunized or with one Hib vaccine dose received before age 12 months = give 2 addiQonal doses 8 weeks apart.

• With >/= 2 Hib vaccine doses received before age 12 months = give 1 additional dose, at least 8 weeks after previous dose

Haemophilus influenzae type b Conjugate Vaccine (Hib vaccine)

.For children </= 5 years old who received a Hib vaccine dose(s) during or within 14 days of starting therapy or during therapy

Repeat the dose(s) of Hib vaccine at least 3 months a>er compleQon of therapy (based on the recommended schedule for high-risk children).

Haemophilus influenzae type b Conjugate Vaccine (Hib vaccine)

For children who are hematopoieDc stem cell transplant recipients

Revaccination with 3 doses of Hib vaccine 4 weeks apart, starting 6 to 12 months after transplant, regardless of age and vaccination history.

Haemophilus influenzae type b Conjugate Vaccine (Hib vaccine)

For unimmunized children: >/= 15 months of age and undergoing elective splenectomy should be given

1 dose of Hib-containing vaccine at least 14 days before the procedure

Haemophilus influenzae type b Conjugate Vaccine (Hib vaccine)

For unimmunized children: 5 to 18 years old and with either anatomic or functional asplenia (including cell disease) or HIV infection, should be given

1 dose of Hib vaccine.

Tetanus and Diphtheria Toxoid (Td) / Tetanus and Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine

type

Inactivated vaccine

Tetanus and Diphtheria Toxoid (Td) / Tetanus and Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine

min age:

7 years

Tetanus and Diphtheria Toxoid (Td) / Tetanus and Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine

route of admin

Intramuscular (IM)

Tetanus and Diphtheria Toxoid (Td) / Tetanus and Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine

routine vaccination

Ages 7-18 years = 1 dose Tdap (considered as 3rd booster for DTP)

Tdap booster doses should be given

every 10 years for those who have completed* their DTP doses.

If Tdap is not available,

Td can be given.

Completed DTP doses

having received 5 doses of DTP, or 4 doses of DTP if the 4th dose was given on or after the 4th birthday

The NIP provides Td vaccine

at Grade 1 and Grade 7 as part of their school-based immunization program.

Tetanus and Diphtheria Toxoid (Td) / Tetanus and Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine

CATCH-UP RECOMMENDATION: For unvaccinated children ages 7-18 years old (primary)

• Dose 1 to 2: interval of 4 weeks

• Dose 2 to 3: interval of 6 months

Tetanus and Diphtheria Toxoid (Td) / Tetanus and Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine

CATCH-UP RECOMMENDATION: For unvaccinated children ages 7-18 years old (booster)

• Dose 3 to 4: interval of at least 1 year

• Dose 4 to 5: interval of at least 1 year

Use Tdap as

one of the 5 doses, preferably as first dose

Tetanus and Diphtheria Toxoid (Td) / Tetanus and Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine

CATCH-UP RECOMMENDATION: For ages 7–9 years with incomplete DTP doses:

give one dose Tdap and another dose at age 11–12 years

Tetanus and Diphtheria Toxoid (Td) / Tetanus and Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine

CATCH-UP RECOMMENDATION: For ages 10-18 years with incomplete DTP doses:

give one dose Tdap and every 10 years thereafter

Tetanus and Diphtheria Toxoid (Td) / Tetanus and Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine

CATCH-UP RECOMMENDATION: For DTaP inadvertently administered on or aber age 7 years: (7-9)

DTaP may count as part of catch-up series.

Administer adolescent Tdap booster dose at age 11–12 years

Tetanus and Diphtheria Toxoid (Td) / Tetanus and Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine

CATCH-UP RECOMMENDATION: For DTaP inadvertently administered on or aber age 7 years: (10-18)

Count dose of DTaP as the adolescent Tdap booster dose

Tetanus and Diphtheria Toxoid (Td) / Tetanus and Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine

SPECIAL CONSIDERATIONS: History of tetanus-toxoid containing vaccine: Unknown or < 3 doses

• Tdap/Td

• Tdap/Td

Tetanus and Diphtheria Toxoid (Td) / Tetanus and Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine

SPECIAL CONSIDERATIONS: History of tetanus-toxoid containing vaccine: 3 or more

• Tdap/Td, if >/= 10 years since last tetanus-containing vaccine dose

• Tdap/Td, if >/= 5 years since last tetanus-containing vaccine dose

Tdap is preferred for persons age >/= 11 years who

have not previously received Tdap or whose Tdap history is unknown.